Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Fibrosis Therapeutic Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for KIAA1199/CEMIP drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | KIAA1199/CEMIP Recombinant Protein (ECD) High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native glycosylation. |
View KIAA1199 Products |
| Gene Delivery | KIAA1199/CEMIP Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and functional migration assays. |
View KIAA1199 Products |
| Benchmark Ab | Anti-KIAA1199/CEMIP Recombinant Antibody Recombinant positive control for functional blocking and IP/WB validation. |
View KIAA1199 Products |
| Validator | KIAA1199/CEMIP siRNA Set Target-specific knockdown verification in cell-based migration assays. |
View KIAA1199 Products |
| Related Target A | CD44 Primary cell-surface receptor for hyaluronan; acts synergistically in CEMIP-mediated metastasis. |
View CD44 Products |
| Related Target B | HAS2 (Hyaluronan Synthase 2) Synthesizes the high-molecular-weight hyaluronan substrate cleaved by CEMIP. |
View HAS2 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Post-Translational Glycosylation requirements for activity | HEK293 mammalian expression system preserves native N-glycosylation essential for CEMIP secretion and function. |
| In vitro Hyaluronan (HA) Depolymerization Assay validation | Sequence-verified, high-purity soluble CEMIP proteins with theoretical MW verification via SDS-PAGE. |
| Lack of Validated Controls | Sequence-defined recombinant benchmark antibodies available as functional positive controls. |
| Off-target assay interference | Highly specific siRNA validation sets included to rule out background hyaluronidase (HYAL1/2) activity. |
Live KIAA1199/CEMIP R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for KIAA1199/CEMIP therapeutics is intensifying, with major players shifting focus from traditional intracellular targets to secreted protein inhibition. As first-generation therapies targeting the tumor microenvironment reach the clinic, the next wave of R&D is targeting CEMIP-mediated hyaluronan degradation to reverse immune exclusion in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (Blocking) | Academic/Biotech Consortiums | Colorectal Cancer, Gastric Cancer | Functional blocking assays requiring highly pure, native-conformation soluble CEMIP antigen. |
| Small Molecule Inhibitor | Preclinical Discovery Stage | Osteoarthritis, Idiopathic Pulmonary Fibrosis | High-throughput enzyme assays requiring stable, batch-consistent recombinant CEMIP protein. |
| RNA Therapeutics (siRNA/ASO) | RNAi Therapeutics Developers | Metastatic Solid Tumors | Validated transfection-grade siRNA controls and stable target overexpression lentiviruses. |